Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986712 | 0.91 | HDAC6 (0.37) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL19133186 | 0.85 | TSHR (0.33) | TSHRTHPOMAPTEHMT2TDP1 | |
| SCHEMBL28319882 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL21784320 | 0.77 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL6512969 | 0.76 | CA12 (0.32) | CA14 | |
| SCHEMBL6512974 | 0.76 | HDAC3 (0.30) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL13897101 | 0.76 | CA14 (0.33) | CA14 | |
| SCHEMBL865291 | 0.75 | HDAC6 (0.40) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL343348 | 0.75 | HDAC6 (0.40) | TDP1HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL1906455 | 0.75 | HDAC6 (0.40) | TDP1HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117025286-B | Modified high-bearing gear oil and production process thereof | 山东北方淄特特种油股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-117025286-B | Modified high-bearing gear oil and production process thereof | 山东北方淄特特种油股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117025286-A | Modified high-bearing gear oil and production process thereof | 山东北方淄特特种油股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-115996755-A | Bifunctional molecules and methods of use thereof | 旗舰创业创新VI有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023049816-A2 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| EP-4138858-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4138857-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4126063-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Flagship Pioneering, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11484599-B2 | Polymer conjugate vaccines | THE UNIVERSITY OF CHICAGO (US) | 2022-11-01 | — | — | US | disclosed |
| CN-108770357-B | Polymer conjugate vaccines | 芝加哥大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20220305135-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2022-09-29 | — | — | US | disclosed |
| EP-3976061-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | The University of Chicago (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206355-A | Methods and compositions for treating cancer with cancer-targeting adjuvants | 芝加哥大学 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484599-B2 | Polymer conjugate vaccines | CD14, TLR3, TLR1 | TSHR 1379/4885THPO 458/4885MAPT 1182/4885 |
| US-20220305135-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS | TLR3, TLR6, TLR2 | TSHR 2525/4885THPO 306/4885MAPT 3512/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | TSHR 1132/4885THPO 3701/4885MAPT 386/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | TSHR 3164/4885THPO 4337/4885MAPT 4546/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | TSHR 3164/4885THPO 4337/4885MAPT 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.